La chaîne d'options affiche les données clés des options sur actions de SMX (Security Matters) à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour SMX (Security Matters)..

SMX (Security Matters) (NASDAQ:SMX) Stock, Chaîne d'Options

SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Integra Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#AMEX">ITRG</a>) with a Buy and raises the price target from $2.75 to $3.25.

News

Price Target

Analyst Ratings

ITRG

HC Wainwright & Co. Maintains Buy on Integra Resources, Raises Price Target to $3.25

BMO Capital analyst Keith Bachman maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Outperform and lowers the price target from $745 to $650.

HUBS

BMO Capital Maintains Outperform on HubSpot, Lowers Price Target to $650

BMO Capital analyst Keith Bachman maintains IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) with a Market Perform and raises the price target from $260 to $300.

BMO Capital Maintains Market Perform on IBM, Raises Price Target to $300

Earnings

HBAN

Huntington Bancshares Q2 2025 EPS $0.34 Misses $0.35 Estimate, Sales $1.954B Miss $1.972B Estimate

Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) has received a bullish price target of $248 from BofA Securities, thanks to its successful Prime Day event.
What Happened: BofA Securities analyst Justin Post has reaffirmed a Buy rating for Amazon&#8217;s stock, setting a $248 price target. This decision follows an evaluation of the Prime Day performance, as reported <a href="https://www.insidermonkey.com/blog/amazons-prime-day-success-fuels-bofas-bullish-248-price-target-1570641/?amp=1">by</a> Insider Monkey on Thursday.
The firm&#8217;s analysis indicates that Prime Day generated a staggering $21.4 billion in Gross Merchandise Value (GMV), marking a 60% increase from the previous year.
Despite the event lasting twice as long as in 2024, the average sales dropped by 20%, while the overall sales increased. The analysis also predicts a 55% year-over-year growth in first-party sales, reaching $11.45 billion, and a 67% year-over-year growth in third-party sales, reaching $9.95 billion.
See Also: <a href="https://benzinga.com/markets/commodities/25/07/46469746/canada-hits-back-at-trumps-50-steel-tariffs-with-1-billion-rescue-new-quota-system" target="_blank" rel="noopener">Canada Hits Back At Trump&#8217;s 50% Steel Tariffs With $1 Billion Rescue, New Quota System</a>
Why It Matters: This bullish outlook comes after a series of events that had initially cast a shadow on Amazon&#8217;s prospects. Early Prime Day sales figures were <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46302633/amazon-stock-slips-as-early-prime-day-sales-data-disappoints">reported to be lower</a> than the previous year&#8217;s, causing a dip in the company&#8217;s stock.
However, this latest analysis of the event&#8217;s performance has turned the tide, leading to a more optimistic forecast for the company.
Moreover, Amazon&#8217;s <a href="https://www.benzinga.com/markets/tech/25/07/46336890/amazon-may-pour-billions-more-into-anthropic-as-13-8-billion-ai-bet-grows-report">commitment to investing billions</a> more into Anthropic, an AI model builder, and the continuous selling of Amazon stock by its founder and executive chairman, Jeff Bezos, have been notable occurrences in the company&#8217;s recent history.
Price Action: Amazon ended Thursday at $223.88, gaining 0.31%, and inched up another 0.23% in pre-market trading, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://benzinga.com/real-estate/25/07/46458782/barbara-corcoran-who-sold-her-real-estate-empire-for-66-million-decades-ago-says-this-is-the-most-und" target="_blank" rel="noopener">Barbara Corcoran, Who Sold Her Real Estate Empire For $66 Million Decades Ago, Says This Is The &#8216;Most Under-Utilized&#8217; Tool In The Workplace</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Markets

AMZN

Amazon's $21.4 Billion Prime Day Haul Ignites Wall Street Hype: BofA Predicts Over 10% Upside Amid Soaring AI Momentum

FOXO

FOXO Technologies To Spin Off Epigenetics Unit FOXO Labs, Aiming To Unlock Value With AI-Driven Health Insights

BMO Capital analyst Andrew Strelzik upgrades Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) from Market Perform to Outperform and raises the price target from $56 to $65.

Upgrades

BMO Capital Upgrades Chipotle Mexican Grill to Outperform, Raises Price Target to $65

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial for OCU410ST&nbsp;(AAV5-hRORA)—a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies).
"Dosing the first patient is an especially significant milestone and brings us closer to our goal of addressing the unmet medical need that exists for all Stargardt patients—100,000 in the U.S. and Europe and 1 million worldwide," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "Progressing our second modifier gene therapy candidate into a registration clinical trial is a pivotal step in potentially providing a one-time therapy for life for the millions of patients affected by inherited retinal diseases."
The Phase 2/3 clinical trial for OCU410ST builds upon encouraging results and positive data from the Phase 1 GARDian trial, which demonstrated 48% slower lesion growth at 12-month follow up in evaluable treated eyes compared to untreated eyes. Additionally, evaluable treated eyes showed a statistically significant (p=0.031) and clinically meaningful improvement of nearly 2-line gain in best corrected visual acuity (BCVA) at 12-month follow-up when compared to untreated eyes.
OCU410ST maintains a favorable safety and tolerability profile with no serious adverse events or adverse events of special interest, including ischemic optic neuropathy, vasculitis, intraocular inflammation, endophthalmitis or choroidal neovascularization.
The Phase 2/3 study will enroll 51 participants diagnosed with Stargardt disease. Of these, 34 will receive a one-time subretinal injection of OCU410ST (200 μL at a concentration of 1.5 × 10¹¹ vector genomes/mL) in the eye with poorer visual acuity, while 17 will be assigned to an untreated control group. The primary objective of the trial is to evaluate the reduction in atrophic lesion size. Key secondary endpoints include improvements in BCVA and low luminance visual acuity (LLVA), compared to controls. Data from the one-year follow-up will be used to support the company's planned Biologics License Application (BLA).
The OCU410ST Phase 2/3 pivotal confirmatory trial represents Ocugen's second late-stage clinical program. Ocugen plans to submit a BLA for OCU410ST in 2027 in alignment with its strategic goal of filing three BLAs over the next three years.

OCGN

Ocugen Reports First Patient Dosed In Phase 2/3 GARDian3 Clinical Trial For OCU410ST, Modifier Gene Therapy Candidate Being Developed For All Stargardt Disease

Keybanc analyst Philip Gibbs upgrades Materion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTRN#NYSE">MTRN</a>) from Sector Weight to Overweight and announces $112 price target.

MTRN

Keybanc Upgrades Materion to Overweight, Announces $112 Price Target

CDLR

Cadeler Takes Early Delivery Of Wind Keeper, Secures EUR210M Vestas Contract For Offshore Wind Work Starting 2026

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) affirms FY2025 GAAP EPS guidance from $15.00-$15.50 to $15.00-$15.50 vs $15.23 analyst estimate. Affirms FY2025 sales outlook from $71.225 billion-$72.544 billion to $71.225 billion-$72.544 billion vs $71.313 billion estimate.

Guidance

American Express Affirms FY2025 Sales Guidance of $71.225B-$72.544B vs $71.313B Est

Sonim Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) (the "Company") and Social Mobile today announced that they have entered into a definitive agreement under which Social Mobile will acquire the assets and substantially all current liabilities of Sonim Technologies at $20 million including a $5 million potential earn-out in an all-cash transaction.
This acquisition aligns with Social Mobile's strategy to expand its footprint in the purpose-built enterprise mobility market. Sonim's expertise in mission-critical mobile solutions complements Social Mobile's custom enterprise mobility offerings, creating a powerful synergy to deliver innovative, secure, and scalable solutions for customers worldwide.
The agreement is approved by Sonim's Board of Directors. The transaction is expected to close in Q4 2025, subject to customary closing conditions, including shareholder and regulatory approvals.

SONM

Social Mobile to Acquire Sonim Technologies in $20M Deal to Boost Enterprise Mobility Reach

Baird analyst Wesley Golladay initiates coverage on American Healthcare REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHR#NYSE">AHR</a>) with a Outperform rating and announces Price Target of $41.

Initiation

Baird Initiates Coverage On American Healthcare REIT with Outperform Rating, Announces Price Target of $41

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54292459&amp;newsitemid=20250717218246&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=11347020056e3dfcf47ccb9b4ccb9302">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl&#xAE;(luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions did not meet its primary endpoint of RBC transfusion independence during any consecutive 12-week period, starting within the first 24 weeks of treatment, compared to placebo (p=0.0674). Patients saw a numerical and clinically meaningful improvement in RBC transfusion independence favoring Reblozyl, in line with previous results from the Phase 2 trial (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03194542%3Fcond%3Dmyelofibrosis%26term%3Dluspatercept%26checkSpell%3D%26rank%3D3&amp;esheet=54292459&amp;newsitemid=20250717218246&amp;lan=en-US&amp;anchor=NCT03194542&amp;index=2&amp;md5=4f18f4ee81c128936c5bbe7b293149ac">NCT03194542</a>).
Several important secondary measures also showed a clinically meaningful benefit favoring Reblozyl, which included a higher number of patients who achieved at least a 50% reduction (and by at least 4 RBC units) in RBC transfusion burden, as well as a higher number of patients achieving a hemoglobin (Hb) level increase by at least 1 g/dL while remaining transfusion independent for at least 12 consecutive weeks.
Frequently observed treatment emergent adverse events were consistent with the known safety profile of Reblozyl previously reported across indications.
The company is encouraged by the clinically meaningful results of the study and will engage with the FDA and EMA to discuss the submission of marketing applications.
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require RBC transfusions, treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), and treatment of anemia in adult patients with beta thalassemia who require RBC transfusions.
Bristol Myers Squibb thanks the patients, investigators and clinical trial sites who participated in the INDEPENDENCE clinical trial.

Bristol Myers Squibb Reports Phase 3 INDEPENDENCE Trial Misses Primary Endpoint In Myelofibrosis-Related Anemia Treatment

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) affirms FY2025 GAAP EPS guidance from $15.00-$15.50 to $15.00-$15.50 vs $15.23 analyst estimate..

American Express Affirms FY2025 GAAP EPS Guidance of $15.00-$15.50 vs $15.23 Est

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) reported quarterly earnings of $4.08 per share which beat the analyst consensus estimate of $3.87 by 5.51 percent. This is a 16.91 percent increase over earnings of $3.49 per share from the same period last year. The company reported quarterly sales of $17.856 billion which beat the analyst consensus estimate of $17.713 billion by 0.81 percent. This is a 9.32 percent increase over sales of $16.333 billion the same period last year.

Earnings Beats

American Express Q2 Adj. EPS $4.08 Beats $3.87 Estimate, Sales $17.856B Beat $17.713B Estimate

VTRS

Viatris' Phase 3 Study Of MR-139 For Blepharitis Misses Primary Endpoint; Next Steps Under Review

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk launched another attack on President Donald Trump over the Jeffrey Epstein client list row amid rising discontentment over the case.
What Happened: The billionaire took to social media platform X to share his thoughts on the case after Trump deemed the Epstein case a "hoax."
"Wow I can't believe Epstein killed himself before realizing it was all a hoax," Musk said in his post on Thursday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Wow I can't believe Epstein killed himself before realizing it was all a hoax
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1945967524564369877?ref_src=twsrc%5Etfw">July 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
However, the billionaire was also seen coming to the defense of the President after WSJ reported <a href="https://www.wsj.com/politics/trump-jeffrey-epstein-birthday-letter-we-have-certain-things-in-common-f918d796?st=eGnQWo&amp;reflink=desktopwebshare_permalink">on</a> Thursday, claiming to have reviewed a 2003 lewd birthday letter to Epstein by Trump for Epstein's 50th birthday as part of an album collected by Epstein's wife, Ghislaine Maxwell. Trump has since <a href="https://www.benzinga.com/news/politics/25/07/46486660/trump-directs-pam-bondi-to-release-more-epstein-documents-subject-to-court-approval-threatens-legal-action-against-wsj-over-epstein-letter">threatened to sue</a> WSJ over the claims.
Musk prompted Grok, asking the xAI model to verify whether the letter was false or true in a reply to a post on X. The billionaire then reposted Grok's explanation on the claim, which Grok identified as false.
"Grok, is the letter most likely fake or true?" Musk asked in his post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/grok?ref_src=twsrc%5Etfw">@grok</a> Is the letter most likely fake or true?
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1946060849132577181?ref_src=twsrc%5Etfw">July 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Most likely fake. The letter&#39;s cryptic, third-person script doesn&#39;t match Trump&#39;s direct style or known handwriting (he uses Sharpie notes). No photo for signature verification, and allies confirm it&#39;s uncharacteristic. WSJ claims DOJ review, but timing amid Epstein file…
&mdash; Grok (@grok) <a href="https://twitter.com/grok/status/1946061285474636000?ref_src=twsrc%5Etfw">July 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The news comes as Musk had <a href="https://www.benzinga.com/news/politics/25/07/46270547/elon-musk-reignites-jeffrey-epstein-client-list-row-adding-fuel-to-the-feud-with-trump">reignited the Epstein row</a>, calling on the Trump administration to release the files as tensions rose between the pair following disagreements over the Big Beautiful Bill law.
In what could be perceived as an anti-Musk move, Trump recently appointed Jonathan Morrison, a Tesla critic, as his nominee to lead the NHTSA. Morrison had called for <a href="https://www.benzinga.com/markets/tech/25/07/46434613/elon-musks-tesla-could-face-stricter-oversight-as-trumps-nhtsa-pick-targets-autonomous-driving-cannot-sit-back">tougher oversight of autonomous vehicles</a> in the U.S., which could create hurdles for Tesla's robotaxi ambitions.
The company's FSD tech has already been under scrutiny by the NHTSA for <a href="https://www.benzinga.com/markets/tech/25/06/46067027/tesla-robotaxi-faces-nhtsa-scrutiny-over-traffic-violations-during-austin-launch">possible traffic violations</a> committed by the Robotaxis during Austin's launch event in June.
Trump's Big Beautiful Bill, which gets rid of <a href="https://www.benzinga.com/markets/tech/25/07/46289556/trumps-tax-bill-axes-the-7500-ev-credit-heres-how-you-can-still-claim-it">the $7,500 EV credit</a>, also effectively makes the ZEV credits, which earned Tesla <a href="https://www.benzinga.com/markets/tech/25/07/46258669/tesla-made-2-76-billion-from-zev-credits-in-2024-in-us-but-trumps-tax-bill-just-killed-this-revenue-stream">billions in revenue last year</a>, redundant by relaxing CAFE or Corporate Average Fuel Economy norms.
The norms dictate that each car should drive a certain number of miles on a gallon of fuel. Violating the norms by failing to meet the figures would result in hefty fines for automakers.
With relaxed norms, automakers wouldn't have to worry about violating the norms due to decreased fuel economy requirements, buying a lesser amount of <a href="https://www.benzinga.com/markets/tech/25/07/46385263/tesla-rival-rivian-could-lose-a-major-revenue-stream-due-to-a">ZEV credits from companies</a> like Tesla to comply.
Elsewhere, Tesla has also been under fire for Musk's political activities with the America Party, with experts like Gerber Kawasaki's co-founder Ross Gerber claiming that the company has <a href="https://www.benzinga.com/markets/tech/25/07/46337215/tesla-is-basically-hijacked-by-elon-musk-says-ross-gerber-calling-it-completely-ridiculous-america-party-is-the-worst-news-for-tsla">been "hijacked" by Musk</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="206" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18061104/TSLA-JUL-18-2025-2-1024x206.jpg" alt="" class="wp-image-991213" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18061104/TSLA-JUL-18-2025-2-1024x206.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18061104/TSLA-JUL-18-2025-2-300x60.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18061104/TSLA-JUL-18-2025-2-768x155.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18061104/TSLA-JUL-18-2025-2-1536x310.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18061104/TSLA-JUL-18-2025-2.jpg 1563w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Tesla offers Satisfactory Momentum and Quality, while scoring well on the Growth metric, but offering poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46487316/elon-musks-xai-unveils-sustainable-way-to-cool-memphis-data-center-amid-criticism-from-environmental-rights-groups">Elon Musk&#8217;s xAI Unveils &#8216;Sustainable&#8217; Way To Cool Memphis Data Center Amid Criticism From Environmental Rights Groups</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

TSLA

Elon Musk Attacks Trump For Calling Jeffrey Epstein Case 'A Hoax,' Then Defends Him Against Birthday Letter Leak

SLB Sets 2025 Capital Investment Guidance At $2.4B, Down From 2024, Reflecting ChampionX Deal Impact

SLB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) reported quarterly earnings of $0.74 per share which met the analyst consensus estimate. This is a 12.94 percent decrease over earnings of $0.85 per share from the same period last year. The company reported quarterly sales of $8.55 billion which beat the analyst consensus estimate of $8.47 billion by 0.87 percent. This is a 6.49 percent decrease over sales of $9.14 billion the same period last year.

SLB Q2 Adj. EPS $0.74, Inline, Sales $8.55B Beat $8.47B Estimate

Press Releases

SMX and Aegis Packaging Introduce a Collaborative  'Physical to Digital' Sustainable Packaging Initiative

SMX Enters ASEAN Region: A Strategic Milestone Leap Toward a Global Circular Plastics Future

How SMX Is Turning Trash Into Trade-and Leading a Global Rebalancing

Yes, We Prove It. Unmistakably Ours: How SMX Is Digitizing the Soul of European Craftsmanship

Skypac and SMX Unveil Traceability Alliance for Responsible Plastic Packaging

SMX Ignites ASEAN Expansion with Back-to-Back Packaging Deals - Redefining Global Supply Chain Transparency

SMX Announces $5.5 Million PIPE Offering

SMX's $5.5M Financing Fuels Strategic Ascent in ASEAN Amid Global PET Turmoil

SMX: The Defense Sector's New Weapon in the War for Supply Chain Integrity

SMX Announces Effective Date of Reverse Stock Split

SMXWW

Astrotech

Cemtrex

Digital Ally

Electro-Sensors

Focus Universal

AEye

MultiSensor AI Holdings, Inc. - Common Stock

MultiSensor AI Holdings

Maris Tech

SMX (Security Matters) Public Limited Company - Class A Ordinary Shares

SMX (Security Matters)

Sobr Safe

Sono-Tek

ScanTech AI Systems

SaverOne 2014 Ltd. - American Depositary Shares

Saverone 2014

Universal Security Instruments, Inc. Common Stock

Comments

SMX (Security Matters)

SMX (Security Matters) (SMX) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL